Miltenyi Bioindustry introduces its Baboon Envelope (BaEV) pseudotyped lentiviral vector (LVV) platform, unlocking superior transduction for challenging human primary cells in clinical applications. This platform significantly outperforms vesicular stomatitis virus glycoprotein (VSV-G) LVVs, boosting transduction rates:
Leverage BaEV LVV to enable scalable next-generation cell therapies.